Methamphetamine

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 46602 Experts worldwide ranked by ideXlab platform

Rebecca Mcketin - One of the best experts on this subject based on the ideXlab platform.

  • A study protocol for the N-ICE trial: A randomised double-blind placebo-controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for Methamphetamine (“ice”) dependence
    Trials, 2019
    Co-Authors: Rebecca Mcketin, Peter Higgs, Alyna Turner, Brendan Quinn, Gregory Carter, Olivia M Dean, Paul Dietze, Dan I Lubman, Peter J Kelly, Amanda L. Baker
    Abstract:

    BackgroundThere are currently no approved pharmacotherapies for managing Methamphetamine dependence. N -acetylcysteine (NAC) has been found to reduce the craving for Methamphetamine and other drugs, but its effect on Methamphetamine use and other clinically related endpoints are uncertain. The N-ICE trial is evaluating the safety and efficacy of NAC as a take-home pharmacotherapy for Methamphetamine dependence.Methods/designThis is a two-arm parallel double-blind placebo-controlled three-site randomised trial (ratio 1:1) using permuted block randomisation, with variable block sizes. It is stratified by site, sex and whether the Methamphetamine is injected or not. Participants ( N  = 180; 60 per site) need to be dependent on Methamphetamine, interested in reducing their Methamphetamine use and not currently receiving treatment for substance use disorders. The trial is being conducted in outpatient settings in Melbourne, Geelong and Wollongong, Australia. Participants will receive either 2400 mg oral NAC or a matched placebo, delivered as a take-home medication for 12 weeks. Two 600 mg capsules are self-administered in the morning and two more in the evening. Adherence is being monitored using eCAP™ medication bottle lids, which record the date and time of each occasion the bottle is opened. The primary outcome is Methamphetamine use during the 12-week trial medication period, measured as (a) days of use, assessed using the timeline followback, and (b) Methamphetamine-positive saliva tests, taken weekly. Secondary measures include weekly assessment of Methamphetamine craving, severity of Methamphetamine dependence, Methamphetamine withdrawal symptoms and psychiatric symptoms (depression, suicidality, psychotic symptoms and hostility). Adverse events are monitored at each weekly assessment. Tolerability is assessed using the Treatment Satisfaction Questionnaire for Medication.DiscussionThe N-ICE trial is the first clinical trial to assess whether NAC can reduce Methamphetamine use. This trial will improve our understanding of the potential utility of NAC in managing Methamphetamine dependence and clinically related outcomes. If found to be effective, take-home NAC could be a potentially scalable and affordable pharmacotherapy option for treating Methamphetamine dependence.Trial registrationAustralian and New Zealand Clinical Trials Registry, ACTRN12618000366257 . Registered on 29 May 2018.

  • Methamphetamine and cardiovascular pathology a review of the evidence
    Addiction, 2007
    Co-Authors: Sharlene Kaye, Johan Duflou, Rebecca Mcketin, Shane Darke
    Abstract:

    Aims  To examine the literature pertaining to the cardiovascular effects of Methamphetamine and discuss the implications for Methamphetamine users. Methods  Relevant literature was identified through comprehensive MEDLINE and EMBASE searches. Findings and conclusions  There is sufficient clinical and experimental evidence to suggest that Methamphetamine can have adverse and potentially fatal effects on the cardiovascular system. The existing literature suggests that: (1) Methamphetamine users are at elevated risk of cardiac pathology; (2) risk is not likely to be limited to the duration of their Methamphetamine use, because of the chronic pathology associated with Methamphetamine use; (3) the risk of cardiac pathology is greatest among chronic Methamphetamine users; (4) pre-existing cardiac pathology, due to Methamphetamine use or other factors, increases the risk of an acute cardiac event; and (5) Methamphetamine use is likely to exacerbate the risk of cardiac pathology from other causes, and may therefore lead to premature mortality.

  • Socio-demographic factors associated with Methamphetamine treatment contact among dependent Methamphetamine users in Sydney, Australia
    Drug and Alcohol Review, 2007
    Co-Authors: Rebecca Mcketin, Erin Kelly
    Abstract:

    Australia has a sizable population of dependent Methamphetamine users, the majority of whom do not receive treatment for their drug use. The aim of the current study was to identify socio-demographic factors related to not having received treatment for Methamphetamine use among dependent users of the drug in Sydney, Australia. A cross-sectional survey of Methamphetamine users in Sydney was used to identify a sample of dependent Methamphetamine users (n = 173). Dependence was defined as a score of four or greater on the Severity of Dependence Scale. Dependent Methamphetamine users who had received treatment for their Methamphetamine use (n = 57) were compared with those who had never received treatment for their Methamphetamine use (n = 116) on socio-demographic characteristics and drug use. After adjusting for severity of Methamphetamine dependence, socio-demographic factors that were predictive of not having received Methamphetamine treatment included being female, being born outside Australia and being ...

  • Socio-demographic factors associated with Methamphetamine treatment contact among dependent Methamphetamine users in Sydney, Australia.
    Drug and alcohol review, 2007
    Co-Authors: Rebecca Mcketin, Erin Kelly
    Abstract:

    Australia has a sizable population of dependent Methamphetamine users, the majority of whom do not receive treatment for their drug use. The aim of the current study was to identify socio-demographic factors related to not having received treatment for Methamphetamine use among dependent users of the drug in Sydney, Australia. A cross-sectional survey of Methamphetamine users in Sydney was used to identify a sample of dependent Methamphetamine users (n = 173). Dependence was defined as a score of four or greater on the Severity of Dependence Scale. Dependent Methamphetamine users who had received treatment for their Methamphetamine use (n = 57) were compared with those who had never received treatment for their Methamphetamine use (n = 116) on socio-demographic characteristics and drug use. After adjusting for severity of Methamphetamine dependence, socio-demographic factors that were predictive of not having received Methamphetamine treatment included being female, being born outside Australia and being in full-time employment. Methamphetamine smokers were less likely to receive treatment than people who took the drug via other routes of administration, while primary heroin users who were concurrently dependent on Methamphetamine were unlikely to receive treatment for their Methamphetamine use. Further research is needed to understand the barriers to receiving Methamphetamine treatment among these subgroups of dependent Methamphetamine users.

  • The relationship between crystalline Methamphetamine use and Methamphetamine dependence
    Drug and Alcohol Dependence, 2006
    Co-Authors: Rebecca Mcketin, Erin Kelly, Jennifer Mclaren
    Abstract:

    Abstract Background The aim of the current study was to determine whether crystalline Methamphetamine users are more dependent on Methamphetamine than people who use other forms of the drug, and if so, whether this could be accounted for by their Methamphetamine use history. Method A structured face-to-face interview was used to assess drug use patterns and demographics among a convenience sample of 309 regular Methamphetamine users from Sydney, Australia. Dependence on Methamphetamine in the past year was measured using the Severity of Dependence Scale. The use of crystalline Methamphetamine in the past year was confirmed using a photographic identification sheet. Results Participants who had used crystalline Methamphetamine in the past year were significantly more likely to be dependent on Methamphetamine than participants who took only other forms of Methamphetamine during this time (61% versus 39%). Methamphetamine dependence was also associated with injecting or smoking Methamphetamine (67% and 58%, respectively versus 30% for intranasal or oral use), using Methamphetamine more than weekly (68% versus 34%), having used the drug for more than 5 years (61% versus 36%), and having used ‘base’ Methamphetamine in the past year (59% versus 39%). Crystalline Methamphetamine use remained significantly associated with Methamphetamine dependence after adjusting for these patterns of Methamphetamine use. Conclusions Methamphetamine users who took crystalline Methamphetamine in the past year were more likely to be dependent than Methamphetamine users who had not taken the crystalline form of the drug during this time.

Erin Kelly - One of the best experts on this subject based on the ideXlab platform.

  • Socio-demographic factors associated with Methamphetamine treatment contact among dependent Methamphetamine users in Sydney, Australia.
    Drug and alcohol review, 2007
    Co-Authors: Rebecca Mcketin, Erin Kelly
    Abstract:

    Australia has a sizable population of dependent Methamphetamine users, the majority of whom do not receive treatment for their drug use. The aim of the current study was to identify socio-demographic factors related to not having received treatment for Methamphetamine use among dependent users of the drug in Sydney, Australia. A cross-sectional survey of Methamphetamine users in Sydney was used to identify a sample of dependent Methamphetamine users (n = 173). Dependence was defined as a score of four or greater on the Severity of Dependence Scale. Dependent Methamphetamine users who had received treatment for their Methamphetamine use (n = 57) were compared with those who had never received treatment for their Methamphetamine use (n = 116) on socio-demographic characteristics and drug use. After adjusting for severity of Methamphetamine dependence, socio-demographic factors that were predictive of not having received Methamphetamine treatment included being female, being born outside Australia and being in full-time employment. Methamphetamine smokers were less likely to receive treatment than people who took the drug via other routes of administration, while primary heroin users who were concurrently dependent on Methamphetamine were unlikely to receive treatment for their Methamphetamine use. Further research is needed to understand the barriers to receiving Methamphetamine treatment among these subgroups of dependent Methamphetamine users.

  • Socio-demographic factors associated with Methamphetamine treatment contact among dependent Methamphetamine users in Sydney, Australia
    Drug and Alcohol Review, 2007
    Co-Authors: Rebecca Mcketin, Erin Kelly
    Abstract:

    Australia has a sizable population of dependent Methamphetamine users, the majority of whom do not receive treatment for their drug use. The aim of the current study was to identify socio-demographic factors related to not having received treatment for Methamphetamine use among dependent users of the drug in Sydney, Australia. A cross-sectional survey of Methamphetamine users in Sydney was used to identify a sample of dependent Methamphetamine users (n = 173). Dependence was defined as a score of four or greater on the Severity of Dependence Scale. Dependent Methamphetamine users who had received treatment for their Methamphetamine use (n = 57) were compared with those who had never received treatment for their Methamphetamine use (n = 116) on socio-demographic characteristics and drug use. After adjusting for severity of Methamphetamine dependence, socio-demographic factors that were predictive of not having received Methamphetamine treatment included being female, being born outside Australia and being ...

  • The relationship between crystalline Methamphetamine use and Methamphetamine dependence
    Drug and Alcohol Dependence, 2006
    Co-Authors: Rebecca Mcketin, Erin Kelly, Jennifer Mclaren
    Abstract:

    Abstract Background The aim of the current study was to determine whether crystalline Methamphetamine users are more dependent on Methamphetamine than people who use other forms of the drug, and if so, whether this could be accounted for by their Methamphetamine use history. Method A structured face-to-face interview was used to assess drug use patterns and demographics among a convenience sample of 309 regular Methamphetamine users from Sydney, Australia. Dependence on Methamphetamine in the past year was measured using the Severity of Dependence Scale. The use of crystalline Methamphetamine in the past year was confirmed using a photographic identification sheet. Results Participants who had used crystalline Methamphetamine in the past year were significantly more likely to be dependent on Methamphetamine than participants who took only other forms of Methamphetamine during this time (61% versus 39%). Methamphetamine dependence was also associated with injecting or smoking Methamphetamine (67% and 58%, respectively versus 30% for intranasal or oral use), using Methamphetamine more than weekly (68% versus 34%), having used the drug for more than 5 years (61% versus 36%), and having used ‘base’ Methamphetamine in the past year (59% versus 39%). Crystalline Methamphetamine use remained significantly associated with Methamphetamine dependence after adjusting for these patterns of Methamphetamine use. Conclusions Methamphetamine users who took crystalline Methamphetamine in the past year were more likely to be dependent than Methamphetamine users who had not taken the crystalline form of the drug during this time.

Peymaneh Shirinbayan - One of the best experts on this subject based on the ideXlab platform.

  • SY03-1-6NIDA-ISAM FELLOWSHIPA QUALITATIVE STUDY ON Methamphetamine RELATED SEXUAL HARM IN IRAN
    Alcohol and Alcoholism, 2014
    Co-Authors: Ali Farhoudian, B. Dolatshahee, Najmeh Ahmadpour, Mandana Sadeghi, M. Tavackoli, Omid Massah, E. R. Dogahe, Mohammad Reza Ardakani, Mohammad Farhadi, Peymaneh Shirinbayan
    Abstract:

    Aim. This study aimed to investigate the effects of Methamphetamine use on male high risk sexual behaviors in public and private addiction treatment centers in Tehran. Methods. Using qualitative content analysis of their narrative responses, the statements of Methamphetamine, users their spouses, psychiatrists or physicians who were acclaimed in addiction treatment and research were analysed. Results. Four main categories were determined in the responses of interviewees, each of which possesses a subclass. These classes included “different attitudes to sexual behavior”, “different abilities and sexual risk behaviors”, “the feeling to forced sex” and “difficulties in appropriate sexual behaviors”. Considering these mechanisms, the Methamphetamine use can predispose sexual risk behaviors in Iranian male addicts. Conclusion. Using metamphetamine seems to cause a sharp increase in sexual coercion, sexual risk behaviors and some deviations in one's sexual profile. The implications in preventing the prevalence of HIV infection, sexual education, and harm reduction were discussed.

Tomohisa Mori - One of the best experts on this subject based on the ideXlab platform.

  • Involvement of sigma 1 receptor in the SSRI-induced suppression of the Methamphetamine-induced behavioral sensitization and rewarding effects in mice.
    Japanese journal of psychopharmacology, 2013
    Co-Authors: Mahardian Rahmadi, Mitsutaka Kanazawa, Masahiro Shibasaki, Tomohisa Mori, Tsutomu Suzuki
    Abstract:

    Abstract The abuse of Methamphetamine causes abnormal behaviors which are indistinguishable from schizophrenia in humans. Recent reports have shown that selective serotonin reuptake inhibitors (SSRIs) have beneficial effects on Methamphetamine-related behaviors, including behavioral sensitization and rewarding effects in animals. However, the exact mechanisms by which SSRIs affect Methamphetamine-related behaviors are not yet clear. The present study was designed to investigate the effects of SSRIs on the development of Methamphetamine-induced behavioral sensitization and rewarding effects in mice. Behavioral sensitization was measured by examining the locomotor activity of mice in a tilting cage after repeated injections of Methamphetamine. Repeated administration of Methamphetamine significantly induced a behavioral sensitization. Some SSRIs (fluoxetine and fluvoxamine), which have sigma-1 receptor agonistic activity, inhibited the development of Methamphetamine-induced behavioral sensitization. Fluoxetine also dose-dependently attenuated the rewarding effects of Methamphetamine as measured by the conditioned place preference paradigm. Furthermore, the sigma-1 receptor antagonist NE-100 significantly reversed the inhibitory effects of fluoxetine on Methamphetamine-induced behavioral sensitization and rewarding effects. These results suggest that sigma-1 receptor agonistic activity might be involved in the attenuating effects of fluoxetine and fluvoxamine on Methamphetamine-induced behavioral sensitization and rewarding effects.

  • Behavioral sensitization to the discriminative stimulus effects of Methamphetamine in rats.
    European Journal of Pharmacology, 2004
    Co-Authors: Tsutomu Suzuki, Tomohisa Mori, Yoshie Fukuoka, Mayumi Miyatake, Minoru Narita
    Abstract:

    Sensitization to the discriminative stimulus effects of psychostimulants is not fully understood. Therefore, the present study was designed to investigate the development of sensitization to the discriminative stimulus of Methamphetamine in rats. A dose-response curve for Methamphetamine and a generalization test for cocaine were recorded in rats trained to discriminate between 1.0 mg/kg Methamphetamine and saline. A significant leftward shift of the dose-response curve for Methamphetamine and of the dose-generalization curve for cocaine was observed following repeated administration of Methamphetamine (2.0 mg/kg) instead of saline. These findings suggest that repeated administration of Methamphetamine can produce behavioral sensitization to the discriminative stimulus effects of Methamphetamine in rats.

  • effects of dopamine and serotonin related compounds on Methamphetamine induced self injurious behavior in mice
    Journal of Pharmacological Sciences, 2004
    Co-Authors: Tomohisa Mori, Shinobu Ito, Taizo Kita, Toshiko Sawaguchi
    Abstract:

    Abstract Methamphetamine induces hyperlocomotion, and high doses of Methamphetamine induce self-injurious behavior (SIB) in rodents. It is well known that the monoaminergic system is involved in Methamphetamine-induced behavior. However, the effects of dopamine- and serotonin (5-HT)-related compounds on high-dose Methamphetamine-induced behavior have not been sufficiently clarified. Therefore, the present study was designed to investigate the effects of dopamine receptor antagonists and indirect 5-HT receptor agonists on high-dose Methamphetamine-induced behavior in mice. Methamphetamine (20 mg/kg) initially increased locomotor activity. As the dosage increased, continuous SIB accompanied by a reduction in locomotor activity was observed. The hyperlocomotion and SIB induced by 20 mg/kg of Methamphetamine was abolished by high doses of SCH23390 and haloperidol, indicating that the hyperlocomotion and SIB induced by high doses of Methamphetamine are mediated by the activation of D 1 - and D 2 -receptors. Furthermore, haloperidol (0.1 mg/kg) potently increased locomotor activity in combination with 20 mg/kg Methamphetamine. These results suggest that excess dopaminergic activation, especially activation of dopamine D 2 -receptors, may be involved in the decrease in locomotor activity induced by a high dose of Methamphetamine. On the other hand, indirect 5-HT receptor agonists attenuated Methamphetamine-induced SIB, suggesting that the stimulation of 5-HT receptors plays an important role in high-dose Methamphetamine-induced SIB in mice.

Tsutomu Suzuki - One of the best experts on this subject based on the ideXlab platform.

  • Involvement of sigma 1 receptor in the SSRI-induced suppression of the Methamphetamine-induced behavioral sensitization and rewarding effects in mice.
    Japanese journal of psychopharmacology, 2013
    Co-Authors: Mahardian Rahmadi, Mitsutaka Kanazawa, Masahiro Shibasaki, Tomohisa Mori, Tsutomu Suzuki
    Abstract:

    Abstract The abuse of Methamphetamine causes abnormal behaviors which are indistinguishable from schizophrenia in humans. Recent reports have shown that selective serotonin reuptake inhibitors (SSRIs) have beneficial effects on Methamphetamine-related behaviors, including behavioral sensitization and rewarding effects in animals. However, the exact mechanisms by which SSRIs affect Methamphetamine-related behaviors are not yet clear. The present study was designed to investigate the effects of SSRIs on the development of Methamphetamine-induced behavioral sensitization and rewarding effects in mice. Behavioral sensitization was measured by examining the locomotor activity of mice in a tilting cage after repeated injections of Methamphetamine. Repeated administration of Methamphetamine significantly induced a behavioral sensitization. Some SSRIs (fluoxetine and fluvoxamine), which have sigma-1 receptor agonistic activity, inhibited the development of Methamphetamine-induced behavioral sensitization. Fluoxetine also dose-dependently attenuated the rewarding effects of Methamphetamine as measured by the conditioned place preference paradigm. Furthermore, the sigma-1 receptor antagonist NE-100 significantly reversed the inhibitory effects of fluoxetine on Methamphetamine-induced behavioral sensitization and rewarding effects. These results suggest that sigma-1 receptor agonistic activity might be involved in the attenuating effects of fluoxetine and fluvoxamine on Methamphetamine-induced behavioral sensitization and rewarding effects.

  • Behavioral sensitization to the discriminative stimulus effects of Methamphetamine in rats.
    European Journal of Pharmacology, 2004
    Co-Authors: Tsutomu Suzuki, Tomohisa Mori, Yoshie Fukuoka, Mayumi Miyatake, Minoru Narita
    Abstract:

    Sensitization to the discriminative stimulus effects of psychostimulants is not fully understood. Therefore, the present study was designed to investigate the development of sensitization to the discriminative stimulus of Methamphetamine in rats. A dose-response curve for Methamphetamine and a generalization test for cocaine were recorded in rats trained to discriminate between 1.0 mg/kg Methamphetamine and saline. A significant leftward shift of the dose-response curve for Methamphetamine and of the dose-generalization curve for cocaine was observed following repeated administration of Methamphetamine (2.0 mg/kg) instead of saline. These findings suggest that repeated administration of Methamphetamine can produce behavioral sensitization to the discriminative stimulus effects of Methamphetamine in rats.